NCT03291652 Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential
| NCT ID | NCT03291652 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 140 participants |
| Start Date | 2010-02 |
| Primary Completion | 2026-12-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140 participants in total. It began in 2010-02 with a primary completion date of 2026-12-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).
Eligibility Criteria
Inclusion Criteria: * Inclusion Criteria for the Symptomatic Group: 1. Patient is 30 to 85 years of age, inclusive. 2. Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism, a relevant intracranial atherosclerotic stenosis ≥60%, and MES detected by TCD. 3. Patient who has no contra-indication for the proposed imaging tests. 4. Patient understands the purpose and requirements of the study, and has provided an informed consent. * Inclusion Criteria for the Asymptomatic Group: 1. Patient is 30 to 85 years of age, inclusive. 2. Patient who has a high-grade (\>60%) intracranial stenosis (signal void in MR angiography) but without infarct in the corresponding vascular territory in DWI or T2-weighted sequence. 3. Patient has no MES detected on TCD examination. 4. Patient who has no contra-indication for the proposed imaging tests. 5. Patient understands the purpose and requirements of the study, and has provided an informed consent. Exclusion Criteria: Subject who meets one or more of the following criteria cannot be recruited in the study: 1. Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease, etc. 2. A tandem stenosis \>50% at proximal internal carotid artery. 3. Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \<100 x 109/L), coagulopathy (INR \>1.5). 4. A medical condition that would not allow the patient to adhere to the protocol or complete the study.
Contact & Investigator
Thomas Wai Hong LEUNG, FRCP
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT03291652 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 85 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03291652 currently recruiting?
Yes, NCT03291652 is actively recruiting participants. Contact the research team at drtleung@cuhk.edu.hk for enrollment information.
Where is the NCT03291652 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT03291652 clinical trial?
NCT03291652 is sponsored by Chinese University of Hong Kong. The principal investigator is Thomas Wai Hong LEUNG, FRCP at Chinese University of Hong Kong. The trial plans to enroll 140 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.